Pay in 4 interest-free payments of $6.83 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
27 In vitro activation of the GLP-1R by exendin-4 enhanced osteogenic differentiation while inhibiting adipogenic differentiation of BMSCs
The competitive landscape for obesity medications continues intensifying
High rates of attrition (12%) were observed in Altimmunes trials, and 5% of patients on semaglutide discontinued treatment due to nausea, vomiting or diarrhea (with 25-44% of patients reporting symptoms)
Eli Lilly's trial results, published in the New England Journal of Medicine last year, followed 338 overweight and obese adults for 48 weeks
Propensity score matching (PSM) was employed to create two cohorts: A GLP-1 agonists group and a control group without GLP-1 agonists usage
Glucagon-like peptide 1 (GLP-1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials
US$ 19.99
US$ 25.60
US$ 28.78
US$ 27.62
US$ 27.55
